Cardiomyocytes Market - Top Companies and Manufacturers

Top Featured Companies Dominating the Cardiomyocytes Landscape

AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Novartis
Pfizer
Roche
Johnson & Johnson
Merck & Co., Inc.
Bayer
Abbott Laboratories
Bristol Myres
Cytiva

Browse Key Market Insights with Data Illustration:

Cardiomyocytes Market - Global Forecast Report 2036

In the News

31^st January 2024

Abbott Park, Illinois /PRNewswire/ -- The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.

6^th December 2023

Novartis announced that Fabhalta® (iptacopan) has been approved by the U.S. Food and Drug Administration (FDA) as the first oral monotherapy for the management of adults suffering from paroxysmal nocturnal hemoglobinuria (PNH)1. A Factor B inhibitor, fabhalta functions proximally in the immune system's alternative complement pathway, offering complete regulation of the destruction of red blood cells (RBCs) both inside and outside of blood vessels (intra- and extravascular hemolysis [IVH and EVH]).

Frequently Asked Questions (FAQ)

The major factors driving the growth of the Cardiomyocytes market are the rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.

The market size of cardiomyocytes is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.

The Human iPSC-derived Cardiomyocytes segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Cardiomyocytes Market - Top Companies and Manufacturers

Top Featured Companies Dominating the Cardiomyocytes Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the cardiomyocytes market?

What would be the CAGR of the cardiomyocytes market over the forecast period?

Who are the major players dominating the cardiomyocyte market?

Which segment captures the largest market size in the type segment in the cardiomyocytes market?

Which region will provide more business opportunities for the growth of the cardiomyocytes market in the future?